Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting DisclosuresGlobeNewsWire · 2 days ago
Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with TurinBusiness Wire · Oct 8, 2026
Simulations Plus Announces Completion of Acquisition by AltarisBusiness Wire · Oct 6, 2026
Simulations Plus (NASDAQ:SLP) Stock Crosses Above 200-Day Moving Average – Here’s What HappenedDefense World · Sep 24, 2026
Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science BranchBusiness Wire · Sep 17, 2026
Squarepoint Ops LLC Sells 58,282 Shares of Simulations Plus, Inc. $SLPDefense World · Sep 16, 2026Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 9, 2026 | $0.23 | $0.30 | Beat |
| Apr 9, 2026 | $0.27 | $0.35 | Beat |
| Jan 8, 2026 | $0.18 | $0.13 | Miss |
| Dec 1, 2025 | $0.10 | $0.10 | Beat |
| Jul 14, 2025 | $0.26 | $0.45 | Beat |
| Apr 3, 2025 | $0.25 | $0.31 | Beat |